Could a common anesthetic help prevent liver cancer from coming back?
NCT ID NCT07657897
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether adding lidocaine to standard sedation during radiofrequency ablation for liver cancer can reduce inflammation and lower the chance of the cancer returning. The researchers focus on a process called NETosis, which is linked to tumor growth and spread. One hundred people with small liver tumors (up to 3 cm) will be randomly assigned to receive either standard sedation or sedation plus lidocaine, and their outcomes will be tracked for one year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lidocaine
What this could lead to
If lidocaine reduces NETosis and recurrence, it could offer a simple, low-cost way to improve outcomes after liver cancer ablation.
What could go wrong
This is a small, early-stage study (100 participants) testing a biomarker-driven idea; results may not confirm benefit, and lidocaine's effect on recurrence is unproven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEDATION AND ANALGESIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
"Prof. Dr. Octavian Fodor" Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca, Romania
RECRUITINGCluj-Napoca, Cluj, 400394, Romania
Contact Phone: •••-•••-•••• Email: •••••@•••••